Patents by Inventor Scott David Gorman

Scott David Gorman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimeric antibody, pharmaceutical composition and process of its production
    Patent number: 7098006
    Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species. An antibody which is capable of binding to human CD4 antigen is also provided together with a pharmaceutical composition comprising the antibody.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: August 29, 2006
    Assignee: Burroughs Wellcome Co.
    Inventors: Scott David Gorman, Michael Ronald Clark, Stephen Paul Cobbold, Herman Waldmann
  • Altered antibodies and their preparation
    Patent number: 6767996
    Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.
    Type: Grant
    Filed: May 17, 1993
    Date of Patent: July 27, 2004
    Assignee: Glaxo Wellcome Inc.
    Inventors: Scott David Gorman, Michael Ronald Clark, Stephen Paul Cobbold, Herman Waldmann
  • Antibodies with binding affinity for the CD3 antigen
    Patent number: 5968509
    Abstract: An antibody or antibody fragment with a binding affinity for the CD3 antigen, having a human constant region, and human or rat variable framework region, a heavy chain with CDRs having the amino acid sequences:(a) Ser-Phe-Pro-Met-Ala (SEQ ID NO:1),(b) Thr-Ile-Ser-The-Ser-Gly-Gly-Arg-Thr-Tyr-Tyr-Arg-Asp-Ser-Val-Lys-Gly (SEQ ID NO:2),(c) Phe-Arg-Gln-Tyr-Ser-Gly-Gly-Phe-Asp-Tyr (SEQ ID NO:3),and light chain with CDRs having the amino acid sequences:(d) Thr-Leu-Ser-Ser-Gly-Asn-Ile-Glu-Asn-Tyr-Val-His (SEQ ID NO:4),(e) Asp-Asp-Asp-Lys-Arg-Pro-Asp (SEQ ID NO:5),(f) His-Ser-Tyr-Val-Ser-Ser-Phe-Asn-Val (SEQ ID NO:6),in which the heavy chain CDRs are arranged in the order (a), (b), (c) in the leader.fwdarw.constant region direction and the light chain CDRs are arranged in the order (d), (e), (f) in the leader.fwdarw.constant region direction.
    Type: Grant
    Filed: December 23, 1994
    Date of Patent: October 19, 1999
    Assignee: BTP International Limited
    Inventors: Scott David Gorman, Edward Graham Routledge, Herman Waldmann
  • Altered antibodies and their preparation
    Patent number: RE43898
    Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.
    Type: Grant
    Filed: September 16, 1991
    Date of Patent: January 1, 2013
    Assignee: Glaxo Wellcome Inc. Research
    Inventors: Scott David Gorman, Michael Ronald Clark, Stephen Paul Cobbold, Herman Waldmann
  • Altered antibodies and their preparation
    Patent number: RE46877
    Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: May 29, 2018
    Assignee: BTG INTERNATIONAL LIMITED
    Inventors: Scott David Gorman, Michael Ronald Clark, Stephen Paul Cobbold, Herman Waldmann